Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 15/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24810573 | 0.81 | CYP19A1 (0.41) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1649720 | 0.65 | PDK2 (0.37) | KCNH2 | |
| SCHEMBL1587463 | 0.65 | PDK2 (0.37) | KCNH2 | |
| SCHEMBL31309712 | 0.65 | PDK2 (0.37) | KCNH2 | |
| SCHEMBL11448858 | 0.64 | CYP19A1 (0.58) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL12978419 | 0.64 | CYP19A1 (0.58) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL1649644 | 0.63 | KCNA5 (0.38) | — | |
| SCHEMBL31299859 | 0.62 | KDM4E (0.33) | — | |
| SCHEMBL5429399 | 0.62 | CYP11B2 (0.43) | CYP19A1CYP11B2CYP11B1KCNH2CYP17A1 | |
| SCHEMBL2578189 | 0.60 | CHRNB2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022271749-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271749-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |